Floatz logo

Recombinant Human Interleukin-2

ALS (Amyotrophic Lateral Sclerosis)

Institute of Hematology & Blood Diseases Hospital, ChinaN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

12 Active assets in the ALS (Amyotrophic Lateral Sclerosis) cohort.

Asset / SponsorPhaseRating
Ciprofloxacin
NeuroSense Therapeutics Ltd.
Phase 2B
TEONANACATL
University Medical Center Groningen
Phase 2B
Peripheral Blood Mononuclear Cell
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Phase 2B
Monomethyl Fumarate
Institute of Hematology & Blood Diseases Hospital, China
Phase 2B
Treg Cells
The Methodist Hospital Research Institute
Phase 2B

View all 15 →

Same molecule, other indications

Recombinant Human Interleukin-2 is also rated in:

non-Hodgkin lymphomaDormant
B
Indicative ·
60 / 100
View asset →
Brain Injury, AcuteDormant
B
Indicative ·
57 / 100
View asset →
LeukemiaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →